Ipca Laboratories, a Rs.3,200 crore pharma major, has registered impressive financial performance during the first quarter ended June 2014 and its net profit surged sharply by 103 per cent to Rs.145 crore from Rs.72 crore in the corresponding period of last year. EBDITA moved up by 35.4 per cent to Rs.237 crore from Rs.175 crore. Its net sales also improved by 16.7 per cent to Rs.928 crore from Rs.795 crore. EPS worked out to Rs.11.53 as against Rs.5.69 in the last period.
Its export income went up by 14 per cent to Rs.571 crore from Rs.499 crore in the similar quarter of last year. Total revenue from formulations registered growth of 17 per cent to Rs.681 crore from Rs.583 crore. Its sales from domestic branded formulations business also increased by 17 per cent to Rs.293 crore from Rs.250 crore. Similarly, exports of formulations touched to Rs.388 crore as against Rs.333 crore, a growth of 17 per cent.
Ipca's sales of active pharmaceutical ingredients (APIs) moved up by 17 per cent to Rs.247 crore from Rs.212 crore. Its domestic sales of APIs increased by 41 per cent to Rs.64 crore and its export of APIs increased by 10 per cent to Rs.183 crore.
For the full year ended March 2014, Ipca's net sales reached at Rs.4,000 crore and it posted net profit of Rs.477 crore. The company is exporting to over Rs.120 crore and exports account for nearly 61 per cent of its income.